MRVI Q1 2023 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$79M-67.7% YoY

Gross Profit

$45M57.4% margin

Operating Income

$3M3.2% margin

Net Income

-$67,000-0.1% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

-61.4%

Cash Flow

Operating Cash Flow

$85M

Free Cash Flow

$77M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.4B

Stockholders' Equity

$522M

Cash & Equivalents

$628M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$244M	-67.7%
Gross Profit	$45M	$204M	-77.8%
Operating Income	$3M	$167M	-98.5%
Net Income	-$67,000	$67M	-100.1%

Revenue Segments

Nucleic Acid Production Segment

$61M78%

Biologics Safety Testing Segment

$18M22%